Feasibility will be determined at the discretion of the investigator based on the clinical findings at the time of administration. 11.1.6 Incompatibilities There are no known drug interactions associated with the use of MVA-BN and MVA- BN- derived vectors. As stated in Section 11.1.2, no marked toxicities or serious AE s have been noted in clinical trials conducted with MVA -BN and MVA- BN-derived vectors. 12 REFERENCES 56 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 1. Baranova AV, Lobashev AV, Ivanov DV, et al: In silico screening for tumour- specific expressed sequences in human geno me. FEBS Lett 508:143-8, 2001 2. Krukovskaja LL, Baranova A, Tyezelova T, et al: Experimental study of human expressed sequences newly identified in silico as tumor specific. Tumour Biol 26:17-24, 2005 3. Palena C, Polev DE, Tsang KY, et al: The human T-box mesodermal transcription factor Brachyury is a candidate target for T -cell-mediated cancer immunotherapy. Clin Cancer Res 13:2471-8, 2007 4. Herrmann BG, Labeit S, Poustka A, et al: Cloning of the T gene required in mesoderm formation in the mouse. Nature 343:617-22, 1990 5. Kispert A, Hermann BG: The Brachyury gene encodes a novel DNA binding protein. EMBO J 12:4898-9, 1993 6. Edwards YH, Putt W, Lekoape KM, et al: The human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, an d assignment to chromosome 6q27. Genome Res 6:226-33, 1996 7. Kispert A, Koschorz B, Herrmann BG: The T protein encoded by Brachyury is a tissue -specific transcription factor. EMBO J 14:4763-72, 1995 8. Kispert A, Herrmann BG, Leptin M, et al: Homologs of the mouse Brachyury gene are involved in the specification of posterior terminal structures in Drosophila, Tribolium, and Locusta. Genes Dev 8:2137-50, 1994 9.